Integral Health Asset Management, LLC

Integral Health Asset Management, LLC operates as a specialized healthcare-focused hedge fund headquartered in New York, NY, dedicated exclusively to investment opportunities within the healthcare and life sciences sectors. Founded by Brandon Leigh, who serves as Chief Investment Officer, the firm brings concentrated domain expertise to a complex sector requiring deep understanding of clinical development, regulatory pathways, commercial dynamics, and scientific innovation. Filing Form 13F reports with the Securities and Exchange Commission under CIK #0001773206, Integral Health maintains regulatory transparency regarding its long equity positions in publicly traded healthcare securities, though as a hedge fund the firm's complete investment approach likely encompasses both long and short positioning across the healthcare universe. The firm's singular healthcare focus distinguishes it from generalist managers, attracting institutional investors and qualified participants seeking dedicated sector alpha from specialists with the scientific literacy and industry relationships necessary to evaluate pharmaceutical pipelines, biotechnology platforms, and medical device innovations. New York's position as a global financial center and proximity to major pharmaceutical and biotech ecosystems provides strategic advantages for healthcare-focused investment research. The platform provides access to the firm's complete 13F filing history, enabling analysis of disclosed long positions within Integral Health's healthcare-concentrated portfolio.

Integral Health Asset Management, LLC employs a long/short healthcare specialist strategy focused on generating alpha through rigorous fundamental analysis of companies across the healthcare and life sciences sectors. The firm's investment approach combines deep scientific due diligence with assessment of commercial potential, regulatory risk, and competitive positioning, seeking to identify mispriced securities across biotechnology, pharmaceuticals, medical devices, healthcare services, and life sciences tools subsectors. Founder Brandon Leigh's investment process emphasizes primary research including scientific literature analysis, key opinion leader consultations, and clinical trial evaluation to develop differentiated views on drug development outcomes and commercial trajectories. Observable patterns from 13F disclosures reveal concentrated positioning within healthcare, with portfolio construction reflecting high-conviction views on specific therapeutic areas, pipeline catalysts, or secular healthcare trends. Analysis of the 13F Portfolio Composition provides insight into the firm's long book positioning, while Sector Allocation History examination—though concentrated within healthcare—reveals subsector emphases across biotech, pharma, devices, and services over time. The firm's moderate to high turnover characteristics reflect the event-driven nature of healthcare investing, where clinical trial readouts, FDA decisions, and M&A activity create catalysts requiring active portfolio management. Integral Health's specialist focus enables depth of analysis that generalist managers typically cannot replicate.

Integral Health Asset Management, LLC represents a New York-based healthcare specialist hedge fund distinguished by its exclusive sector focus and deep domain expertise in life sciences investing. Founder Brandon Leigh's concentrated approach targets alpha generation through rigorous scientific and commercial analysis of healthcare companies, a methodology requiring specialized knowledge increasingly valued as drug development complexity and regulatory scrutiny intensify. Key analytical dimensions accessible through platform tools include Annualized Return (CAGR) calculations for disclosed long positions and Alpha Generation vs S&P 500 assessment to evaluate sector-specialist value creation relative to broad market alternatives. The 13F disclosures capture the long book component of what is likely a more complete long/short strategy, and analysis should recognize that risk-adjusted performance may differ from long-only reconstruction due to potential hedging activities. Examination of Top 10 Holdings Concentration provides insight into conviction levels and subsector emphases within the healthcare allocation, while longitudinal analysis reveals how positioning adapted through various market environments for life sciences companies. For institutional allocators evaluating specialist healthcare managers, the essential diagnostic question emerges: How has Integral Health's concentrated sector approach navigated the pronounced biotech cycles of recent years—including the 2020-2021 pandemic-driven surge and subsequent 2022-2023 correction—and what does the portfolio's construction reveal about managing idiosyncratic clinical development risk alongside systematic sector factor exposures?

The risk characteristics of Integral Health Asset Management, LLC's disclosed portfolio reflect the concentrated nature of healthcare specialist investing and the inherent volatility of life sciences securities. The firm's Volatility Profile typically exhibits elevated beta to healthcare sector movements and significant idiosyncratic risk from concentrated positions in clinical-stage biotechnology companies where binary outcomes—trial success or failure—can generate dramatic price movements. Historical analysis of Max Drawdown Depth provides insight into how the portfolio navigated sector-specific stress periods including biotech corrections in 2015-2016, 2021 growth stock compression, and 2022 rate-driven multiple contraction particularly severe for unprofitable growth companies. Healthcare investing introduces unique risks including regulatory uncertainty, patent cliffs, competitive pipeline developments, and pricing policy changes that can impact entire subsectors simultaneously. However, the long/short structure potentially employed by the firm—though only long positions are visible in 13F filings—may provide hedging capabilities against sector-wide dislocations while isolating stock-specific alpha. The firm's institutional client base suggests sophisticated risk governance appropriate for concentrated specialist strategies where position sizing and portfolio construction must balance conviction with prudent diversification. Platform users can calculate Downside Capture Ratio metrics for the disclosed long positions, recognizing that complete portfolio risk assessment requires consideration of potential short book hedging.